Clinical Trials Logo

Filter by:
NCT ID: NCT06433687 Not yet recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction

Evaluation of the HekaHeart Platform in Medication Management for Heart Failure Patients

HekaHeart POC
Start date: September 2024
Phase:
Study type: Observational

This pilot study will test the feasibility of a novel digital health technology-enabled platform, HekaHeart, developed to facilitate comprehensive medical management, including medication initiation, titration, e-prescription eligibility, remote patient monitoring, and communication of care coordination activities, for patients with Heart Failure with Reduced Ejection Fraction (HFrEF) not currently on all four pillars of guideline-directed medical therapy (GDMT).

NCT ID: NCT06433635 Not yet recruiting - Depression Clinical Trials

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

SMART-BD
Start date: September 1, 2024
Phase: Phase 4
Study type: Interventional

This is a sequential multiple assignment randomized trial for adults (ages > 18) with a bipolar disorder type 1 diagnosis currently experiencing a depressive episode. It is a randomized pragmatic trial that will compare four commonly prescribed treatments for bipolar depression, which includes three FDA-approved medications (Cariprazine, Quetiapine and Lurasidone) and one antipsychotic/antidepressant combination (Aripiprazole/Escitalopram).

NCT ID: NCT06433505 Not yet recruiting - Healthy Volunteers Clinical Trials

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

Start date: May 30, 2024
Phase: Phase 1
Study type: Interventional

The objective of this study is to assess the pharmacokinetics (PK) and absolute bioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and extent of elimination, and mass balance of BMS-986365.

NCT ID: NCT06433310 Not yet recruiting - Gut Microbiome Clinical Trials

Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study

Start date: May 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to explore how the dietary supplement L-Phenylalanine affects the production of the metabolite phenylpropionic acid (PPA) and changes in fungal populations in the gut microbiome.

NCT ID: NCT06433271 Not yet recruiting - Mental Disorder Clinical Trials

Transdiagnostic Behavior Therapy vs TAU for Adjustment Disorder Following Traumatic Event Exposure

Start date: July 2024
Phase: N/A
Study type: Interventional

Adjustment Disorder (AjD) is the most common mental health condition diagnosed in Active Duty personnel, and is diagnosed following an extreme stress event such as traumatic loss of a comrade, serious accident or injury, or other intense stress event. Despite its high prevalence, no evidence based treatment for AjD has been subjected to randomized controlled trials. This study seeks to build on the research team's pilot work across several disorders study to benefit service members and Veterans with AjD, a highly prevalent but frequently inadequately treated condition. The investigators will compare the effects of Transdiagnostic Behavior Therapy (TBT) vs treatment as usual which is Moving Forward Problem Solving Therapy (TAU-PST) on AjD symptom outcomes. The investigators hypothesize that TBT will result in greater overall symptom reduction compared to TAU-PST.

NCT ID: NCT06433219 Not yet recruiting - Ovarian Cancer Clinical Trials

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Start date: July 26, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objective of the study is to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse.

NCT ID: NCT06433115 Not yet recruiting - Diet Intervention Clinical Trials

Effects of Lean Beef Consumption on Cardiometabolic Health and Gut Microbiome

Start date: May 30, 2024
Phase: N/A
Study type: Interventional

This study is investigating the benefits of lean beef consumption on cardiometabolic health and gut microbiome.

NCT ID: NCT06432985 Not yet recruiting - Clinical trials for Tobacco Use Disorder

Smoking Cessation CM for Veterans With or at Risk for Cancer

CM_TUD_Cancer
Start date: June 30, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Tobacco use among US Veterans poses significant health problems and challenges to their overall well-being. The aim of this project is to evaluate the effectiveness of a program called Contingency Management (CM) in helping Veterans quit smoking during lung cancer screening or cancer care at VA clinics. CM is a behavioral treatment that uses rewards to encourage smoking cessation when verified through biological testing. In the first year, the researchers will develop a mobile CM protocol based on feedback from Veterans and healthcare staff through focus groups. In the second year, they will conduct a pilot study to test the feasibility of the mobile CM program along with counseling and medication for 20 Veterans over a five-week period. The success of the pilot study will determine whether to proceed with a larger randomized controlled trial (RCT) in years three to six, comparing the efficacy of mobile CM with standard treatment. The project will take place at SFVA.

NCT ID: NCT06432725 Not yet recruiting - Hiv Clinical Trials

Joining Under-connected Networks to Optimize "Salud" (Health) ("JUNTOS")

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the JUNTOS Referral Network as an implementation strategy to enhance the reach of HIV-prevention and treatment services to Latino gay, bisexual, and other men who have sex with men (MSM).

NCT ID: NCT06432166 Not yet recruiting - Alzheimer Disease Clinical Trials

2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients

2-HOBA
Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Investigators propose a phase 1b/2a, randomized, double-blind, placebo-controlled, parallel group dose finding and biomarker study to evaluate the safety, tolerability, and biomarker activity of 2-HOBA in 48 MCI/AD participants. Participants will be randomized 1:1:1:1 to receive 250, 500, 750 mg 2-HOBA acetate TID or placebo for 16 weeks. Blood and cerebral spinal fluid (CSF) will be collected to measure markers of protein modification by dicarbonyls (IsoLGs- & MDA), pTau-181, YKL-40, and NF-L.